Sculptra and Radiesse are the two injectables most often called "collagen stimulators" or "biostimulators", and the two word orders of "Sculptra vs Radiesse" draw about 5,400 US searches a month between them (clickstream estimate, October 2026). Clinic pages answering it usually end with a preference. This page does not. It sets the two side by side on what can be checked — what each is made of, what FDA approved and when, what the studies comparing them measured and who paid for them, and what has been reported to FDA — as of 6 October 2026. It is not a recommendation for either. Which, if any, suits a person is a decision for a qualified clinician.
The two at a glance
| Sculptra | Radiesse | |
|---|---|---|
| Material | poly-L-lactic acid (PLLA), a biodegradable polymer | calcium hydroxylapatite (CaHA), a mineral, in a carboxymethylcellulose gel |
| Particles | irregular micro-flakes, about 2–150 µm along the long axis | smooth spheres, about 20–45 µm |
| Supplied as | freeze-dried powder, mixed with sterile water before use | ready-to-inject gel in a syringe; a version with lidocaine, Radiesse (+), since 2015 |
| Maker | Galderma | Merz Aesthetics |
| US approval | PMA P030050 | PMA P050052 (wrinkles) and P050037 (HIV fat loss) |
| Dissolving agent | none | none |
The particle figures come from a 2024 microscopy study that measured both products side by side (McCarthy 2024); the 25–45 µm figure for Radiesse's microspheres also appears in a 2008 review of the product (Jacovella 2008). Neither product is a peptide and neither contains collagen. Our Sculptra explainer covers PLLA in detail.
What FDA has approved, dated
Both are regulated as devices through premarket approval. FDA's approval database, read on 6 October 2026, held 55 records for Sculptra and 170 for Radiesse's main approval. The ones that changed what each device is for:
| Date | Device | What FDA approved |
|---|---|---|
| 3 Aug 2004 | Sculptra | facial fat loss (lipoatrophy) in people with HIV |
| 22 Dec 2006 | Radiesse | moderate to severe facial wrinkles and folds, such as nasolabial folds |
| 22 Dec 2006 | Radiesse | facial fat loss in people with HIV (separate approval, P050037) |
| 28 Jul 2009 | Sculptra | nasolabial folds and other facial wrinkles in immune-competent people |
| 30 Jan 2015 | Radiesse | Radiesse (+), a reformulation with lidocaine |
| 4 Jun 2015 | Radiesse | volume loss in the back of the hands |
| 1 Sep 2021 | Radiesse | Radiesse (+): loss of jawline contour, adults over 21 |
| 25 Apr 2023 | Sculptra | fine lines and wrinkles of the cheek |
| 31 Mar 2026 | Radiesse | diluted 1:2 with saline, décolleté (upper chest) wrinkles, age 22 and over |
Two differences stand out. Radiesse's approvals reach beyond the face — hands since 2015, the upper chest since March 2026 — while every Sculptra approval is facial. And Radiesse now has an approved diluted use: the March 2026 décolleté approval is for the product diluted 1:2 with saline, which makes "hyperdilute" Radiesse an on-label technique in that one area. Sculptra's body uses, including the buttocks, remain off-label; our page on Sculptra on the buttocks sets out that record.
What the comparison studies measured, and who ran them
A PubMed search on 6 October 2026 for PLLA (or Sculptra) together with CaHA (or Radiesse) returned 159 records, mostly reviews and studies of one product that mention the other. Filtered to randomized or comparative studies, it returned 10; read one by one, four compare the two products directly:
| Study | Design | What it measured | Authors' affiliations | Direction |
|---|---|---|---|---|
| Waibel 2024 | randomized, 13 weeks, 21 people, nasolabial area | gene expression in biopsies at day 90 | Galderma (Sculptra's maker) and Alastin, a Galderma company | PLLA "uniquely" linked to fat-cell regeneration genes |
| Waibel 2025 | randomized, 13 weeks, same design | gene expression and pathways | Galderma and Alastin | PLLA "regenerative"; CaHA "pro-inflammatory" |
| McCarthy 2024 | laboratory microscopy of particles | shape, size, roundness | two authors employed by Merz Aesthetics (Radiesse's maker) | CaHA's spheres "may result in reduced inflammatory cell recruitment"; PLLA's flakes "may evoke a more pronounced inflammatory response" |
| Vallejo 2018 | clinical trial, 147 people with HIV fat loss, four fillers | improvement, sessions, volume and cost over 24 months | academic, Spain | patients' own fat was the cheapest; permanent fillers and fat most consistent |
The pattern in the first three rows is the most useful thing a reader can take from this literature. Each maker's research finds the other product more inflammatory. Galderma-affiliated biopsy studies read CaHA as pro-inflammatory and PLLA as regenerative; a Merz-affiliated particle study reads PLLA's irregular flakes as the likelier trigger of inflammation. Neither design measured a clinical outcome a patient would notice — gene activity in a biopsy and particle shape under a microscope are not complication rates. No independent randomized trial comparing the two on appearance, duration or complications was found.
What has been reported to FDA
FDA's MAUDE database collects reports of problems with medical devices. On 6 October 2026 (data last updated 29 September 2026) it held 2,023 reports naming Sculptra and 1,660 naming Radiesse. The most frequently coded patient problems differ:
| Coded patient problem | Sculptra reports | Radiesse reports |
|---|---|---|
| Swelling | 1,195 | 351 |
| Granuloma | 260 | 37 |
| Nodule | 16 | 102 |
| Obstruction / occlusion | 9 | 276 |
| Necrosis | 17 | 179 |
The two profiles point at different known risks. Sculptra's reports are dominated by swelling and granuloma — the delayed lumps that its 2023 labelling update addressed. Radiesse's include 276 reports coding obstruction or occlusion and 179 coding necrosis, the signature of filler entering or compressing a blood vessel and starving the tissue it supplies. That risk applies to any injected filler — Sculptra's own labelling gained a warning on injection into blood vessels in 2016 — and the counts show where it has been reported, not why.
These are counts, not rates. The number of treatments behind each product is not public, reporting is voluntary for patients and clinicians, one event can be filed more than once, and 924 of Sculptra's reports arrived in a single year, 2009, which our Sculptra explainer discusses. A higher count does not by itself mean a higher risk per treatment.
Reversibility: the shared limitation
Hyaluronic-acid fillers, including SKINVIVE, which our reading of the SKINVIVE approval file covers, can be broken down with the enzyme hyaluronidase if something goes wrong. Neither Sculptra nor Radiesse can. Both are left for the body to break down in its own time. Nodules or misplaced product from either are managed by other means, which is one reason the complication records above matter, and why the broader biostimulator and booster category is not interchangeable with ordinary fillers.
What is and is not established
Established: the two are different materials with different particle shapes; Radiesse has more approved uses than Sculptra, including the hands, the jawline and, since March 2026, diluted use on the upper chest, while Sculptra's three approved uses are all facial; neither can be dissolved; the two have different complication profiles in FDA's device reports.
Not established: which lasts longer, which gives better results, or which has the lower complication rate per treatment. No independent head-to-head clinical trial answers any of those, and the studies that do compare the two were largely run by one product's maker or the other. Choosing between them — or neither — is a conversation with a board-certified clinician who can explain their own experience and complication record with each.
Sources
- US FDA, Premarket Approval database via openFDA
device/pma, queried 2026-10-06 (data last updated 2026-09-28):pma_number:P030050(Sculptra, 55 records);pma_number:P050052(Radiesse, 170 records; indication supplements S049 2015-06-04, S052 2015-01-30, S129 2021-09-01, S162 2026-03-31, S148 2023-06-08);P050037(Radiesse, HIV lipoatrophy, 2006-12-22). - US FDA, MAUDE via openFDA
device/event, queried 2026-10-06 (data last updated 2026-09-29):device.brand_name:sculptra(2,023) anddevice.brand_name:radiesse(1,660), with counts bypatient.patient_problems.exactfor swelling, granuloma, nodule, obstruction/occlusion and necrosis. - McCarthy AD, Hartmann C, Durkin A, Shahriar S, Khalifian S, Xie J. A morphological analysis of calcium hydroxylapatite and poly-L-lactic acid biostimulator particles. Skin Res Technol 2024;30(6):e13764. PMID 38853456. Conflict-of-interest statement read.
- Waibel J, Ziegler M, Nguyen TQ, et al. Comparative bulk RNA-seq analysis of poly-L-lactic acid versus calcium hydroxylapatite. Dermatol Surg 2024;50(11S):S166-71. PMID 39480040. Affiliations read.
- Waibel J, Nguyen TQ, Le JHTD, et al. Gene analysis of biostimulators: poly-L-lactic acid triggers regeneration while calcium hydroxylapatite induces inflammation upon facial injection. J Drugs Dermatol 2025;24(1):34-40. PMID 39761144. Affiliations read.
- Vallejo A, Garcia-Ruano AA, Pinilla C, et al. Comparing efficacy and costs of four facial fillers in HIV-associated lipodystrophy: a clinical trial. Plast Reconstr Surg 2018;141(3):613-23. PMID 29135895.
- Jacovella PF. Use of calcium hydroxylapatite (Radiesse) for facial augmentation. Clin Interv Aging 2008;3(1):161-74. PMID 18488886.
- PubMed E-utilities searches, 2026-10-06:
("poly-L-lactic"[tiab] OR PLLA[tiab] OR sculptra[tiab]) AND ("calcium hydroxylapatite"[tiab] OR "calcium hydroxyapatite"[tiab] OR CaHA[tiab] OR radiesse[tiab])(159); with"randomized controlled trial"[pt] OR "comparative study"[pt](10, each read).